Nizoral
(Ketoconazole)ApprovedSmall molecule
Ketoconazole is used to treat fungal infections of the skin, hair, and nails, as well as serious internal fungal infections. It works by stopping the growth of fungus in the body.[2] Nizoral is currently approved and in use across 28 indications[4].[1]
Nizoral is one of 483 small molecule programs targeting Glioma. It is currently in Approved.
28
Indications
117
Total Trials
3
Active Trials
482
Competitors
6
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 28 indications
Competition
Competitive Landscape
314 competitors in Prostate Cancer
#DrugCompanyPhaseTrials
1Nizoral
WWim Janssens
Approved
Androgen Deprivation Therapy
Johnson & JohnsonPhase 3
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Acetylsalicylic Acid
BayerPhase 3
GM-CSF
YY-mAbs Therapeutics
Phase 3
Fluciclovine
UUniversity of Utah
Phase 3
Fuzuloparib
JJiangsu HengRui Medicine Co., Ltd.
Phase 3
Rhpsma-7.3 (18f)
BBlue Earth Diagnostics
Phase 3
Trexall
Jazz PharmaceuticalsPreclinical
Jatenzo
GGrupo Espanol de Tumores Neuroendocrinos
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Prostate Cancer21 trials
Show 18 more trials
Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer
Terminated·—·Phase 1/2·NCT00953576·11 enrolled
Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
Completed·—·Phase 2·NCT00460031·34 enrolled
Neoadjuvant Therapy With Docetaxel and Ketoconazole in Patients With High-Risk Prostate Cancer: A Pilot Study
Unknown status·—·N/A·NCT00870714·20 enrolled
Tics16 trials
Show 13 more trials
Interaction13 trials
Show 10 more trials
ESS4 trials
Effect of Ketoconazole on Breathlessness
Completed·—·Phase 4·NCT01378520·20 enrolled
Neuroblastoma3 trials
N2004-04: Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma
Completed·—·Phase 1·NCT00295919·80 enrolled
41 more indications
Single Dose3 trials
Adult Subject3 trials
Metabolism2 trials
Trial2 trials
Advanced Cancers2 trials
Seborrheic Dermatitis2 trials
Excretion2 trials
Oral2 trials
Patients With Advanced Solid Tumors2 trials
Absorption1 trial
Rehabilitation1 trial
Cohort Study1 trial
Acute Respiratory Distress Syndrome1 trial
Adult1 trial
Investigating the Regulation of Reproductive Hormones in Adult Men
Completed·EEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·N/A·NCT00392457·175 enrolled
Metastatic Melanoma1 trial
Locally Advanced1 trial
Sleep Restriction1 trial
Hormonal Mechanisms of Sleep Restriction
Completed·LLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center·Phase 1·NCT02256865·40 enrolled
Metastatic Prostate Cancer1 trial
Baricitinib1 trial
Pomalidomide1 trial
Unresectable Solid Tumor1 trial
Lymphoma1 trial
Advanced Malignancies1 trial
Fungal Infection1 trial
Advanced Cancer1 trial
Outcome1 trial
Ketoconazole Contributes to Cryptorchidism Outcome Via Modulating Macrophage Trem2
Unknown status·—·N/A·NCT06560086·10 enrolled
Buprenorphine1 trial
Solid Tumors1 trial
Concentration1 trial
Retinopathy1 trial
Effectiveness1 trial
Candidiasis1 trial
Ketoconazole Gel Versus Terconazole Cream for Vaginal Candidiasis
Unknown status·—·Phase 3·NCT03473418·69 enrolled
Malignant Neoplasm1 trial
Autonomous Cortisol Secretion1 trial
Ketoconazole Effects on Cortisol Circadian Rhythm in Mild Autonomous Cortisol Secretion: A Pilot Study
Recruiting·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 1·NCT07649317·36 enrolled
Anatomic Stage IV Breast Cancer AJCC v81 trial
Unspecified8 trials
Show 5 more trials
Regulatory
FDA Approval Timeline[5]
Jan 1, 1982
NIZORAL
NDA NDA018533
Dec 31, 1985
NIZORAL
NDA NDA019084
Aug 31, 1990
NIZORAL
NDA NDA019927
Oct 10, 1997
NIZORAL ANTI-DANDRUFF
NDA NDA020310
Jul 28, 2006
XOLEGEL
NDA NDA021946
Jun 12, 2007
EXTINA
NDA NDA021738
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Nizoral drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Ketoconazole. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Cytochrome P450 51 Inhibitor[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- WWim Janssens